These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21601054)

  • 1. Design of future rabies biologics and antiviral drugs.
    Smith TG; Wu X; Franka R; Rupprecht CE
    Adv Virus Res; 2011; 79():345-63. PubMed ID: 21601054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.
    Haley SL; Tzvetkov EP; Meuwissen S; Plummer JR; McGettigan JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
    Koprowski H
    Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postexposure prophylaxis for rabies in resource-limited/poor countries.
    Shantavasinkul P; Wilde H
    Adv Virus Res; 2011; 79():291-307. PubMed ID: 21601051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein.
    Sun L; Chen Z; Yu L; Wei J; Li C; Jin J; Shen X; Lv X; Tang Q; Li D; Liang M
    Appl Microbiol Biotechnol; 2012 Oct; 96(2):357-66. PubMed ID: 22678022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin.
    Goudsmit J; Marissen WE; Weldon WC; Niezgoda M; Hanlon CA; Rice AB; Kruif Jd; Dietzschold B; Bakker AB; Rupprecht CE
    J Infect Dis; 2006 Mar; 193(6):796-801. PubMed ID: 16479514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approaches to the prevention and eradication of rabies.
    Dietzschold B; Faber M; Schnell MJ
    Expert Rev Vaccines; 2003 Jun; 2(3):399-406. PubMed ID: 12903805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabies research in resource-poor countries.
    Wilde H; Lumlertdacha B
    Adv Virus Res; 2011; 79():449-55. PubMed ID: 21601059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.
    Du Pont V; Plemper RK; Schnell MJ
    Curr Opin Virol; 2019 Apr; 35():1-13. PubMed ID: 30753961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of rabies in the 21st century: curing the incurable?
    Franka R; Rupprecht CE
    Future Microbiol; 2011 Oct; 6(10):1135-40. PubMed ID: 22004032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals.
    Rupprecht CE; Briggs D; Brown CM; Franka R; Katz SL; Kerr HD; Lett S; Levis R; Meltzer MI; Schaffner W; Cieslak PR
    Vaccine; 2009 Nov; 27(51):7141-8. PubMed ID: 19925944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.
    Zhu S; Guo C
    Viruses; 2016 Oct; 8(11):. PubMed ID: 27801824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis.
    Yamada K; Noguchi K; Komeno T; Furuta Y; Nishizono A
    J Infect Dis; 2016 Apr; 213(8):1253-61. PubMed ID: 26655300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of human rabies.
    Jackson AC
    Adv Virus Res; 2011; 79():365-75. PubMed ID: 21601055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccines.
    Franka R; Wu X; Jackson FR; Velasco-Villa A; Palmer DP; Henderson H; Hayat W; Green DB; Blanton JD; Greenberg L; Rupprecht CE
    Vaccine; 2009 Nov; 27(51):7149-55. PubMed ID: 19925945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future tools for global canine rabies elimination.
    Franka R; Smith TG; Dyer JL; Wu X; Niezgoda M; Rupprecht CE
    Antiviral Res; 2013 Oct; 100(1):220-5. PubMed ID: 23871797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.
    Bakker AB; Python C; Kissling CJ; Pandya P; Marissen WE; Brink MF; Lagerwerf F; Worst S; van Corven E; Kostense S; Hartmann K; Weverling GJ; Uytdehaag F; Herzog C; Briggs DJ; Rupprecht CE; Grimaldi R; Goudsmit J
    Vaccine; 2008 Nov; 26(47):5922-7. PubMed ID: 18804136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of systemic injection of rabies immunoglobulin in rabies vaccination.
    Wu W; Liu S; Yu P; Tao X; Lu X; Yan J; Wang Q; Zhang Z; Zhu W
    Arch Virol; 2017 Jun; 162(6):1701-1703. PubMed ID: 28188373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the antiviral drug favipiravir on rabies immunoglobulin for post-exposure prophylaxis of rabies in mice model with category III-like exposures.
    Kimitsuki K; Khan S; Kaimori R; Yahiro T; Saito N; Yamada K; Nakajima N; Komeno T; Furuta Y; Quiambao BP; Virojanapirom P; Hemachudha T; Nishizono A
    Antiviral Res; 2023 Jan; 209():105489. PubMed ID: 36513207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis.
    Kim PK; Ahn JS; Kim CM; Seo JM; Keum SJ; Lee HJ; Choo MJ; Kim MS; Lee JY; Maeng KE; Shin JY; Yi KS; Osinubi MOV; Franka R; Greenberg L; Shampur M; Rupprecht CE; Lee SY
    PLoS One; 2021; 16(9):e0256779. PubMed ID: 34469480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.